ADRB3 and autosomal dominant polycystic kidney disease: To test our hypothesis that selective β3‐AR blockade could potentially have an ameliorative effect on the cystic phenotype by reducing renal cAMP we measured whole‐kidney cAMP levels 4 h after SR59230A (4 mg/kg) administration in ADPKD cystic mice at 13 weeks of age that exhibited Kw/Bw ratios of 0.1 ± 0.05.